ReviewClinical reviews in allergy & immunology2005
Immunopathogenesis of primary sclerosing cholangitis.
Review in Clinical reviews in allergy & immunology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 61 citations in OpenAlex.
- Elevated Liver Fibrosis Progression in Isolated PSC Patients and Increased Malignancy Risk in a PSC-IBD Cohort: A Retrospective Study.International journal of molecular sciences · 2023Article
- Hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis: A prospective observational study.World journal of gastrointestinal surgery · 2023Article
- Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.Biomedicines · 2022Review
- The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia.Auto- immunity highlights · 2020Review
- The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases.International journal of biological sciences · 2020Review
- IgG4 subclass and gamma-glutamyl transferase in children with ulcerative colitis with primary sclerosing cholangitis and without sclerosing cholangitis.Clinical and experimental hepatology · 2019Article
- IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis.Gut and liver · 2019Review
- Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.United European gastroenterology journal · 2018Article
- TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?Clinical reviews in allergy & immunology · 2015Review
- Current research on the treatment of primary sclerosing cholangitis.Intractable & rare diseases research · 2015Review
- Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk.Gastroenterology report · 2014Review
- Role of the microbiota and antibiotics in primary sclerosing cholangitis.BioMed research international · 2013Review
- Approach to a patient with elevated serum alkaline phosphatase.Clinics in liver disease · 2012Review
- Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.World journal of gastroenterology · 2012Review
- Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host disease.American journal of physiology. Gastrointestinal and liver physiology · 2010Article
- Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis.Seminars in immunopathology · 2009Review
- Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?Clinical reviews in allergy & immunology · 2009Review
- Etiopathogenesis of primary sclerosing cholangitis.World journal of gastroenterology · 2008Review
- Perinatal events and the risk of developing primary sclerosing cholangitis.World journal of gastroenterology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology;however, lymphocytic portal tract infiltration is suggestive of an immune-mediated basis for PSC. Associations with inflammatory bowel disease--especially ulcerative colitis--and with other auto-immune diseases, together with genetic associations, further suggest that PSC may be an immune-mediated disease. The immunogenetics of PSC have been the subject of active research, and several human leukocyte antigen (HLA)- and non-HLA-associated genes have been implicated in the development of the disease. Lymphocytes derived from the inflamed gut may enter the liver via the enterohepatic circulation to cause hepatic disease.PSC may be triggered in genetically susceptible individuals by infections or toxins entering the portal circulation through a permeable colon and, therefore, evoking an abnormal immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.